These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35185918)

  • 1. Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy.
    Gonzalez JM; Ballow M; Fairchild A; Runken MC
    Front Immunol; 2022; 13():827305. PubMed ID: 35185918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
    Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
    Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
    Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
    PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
    Martin A; Lavoie L; Goetghebeur M; Schellenberg R
    Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuts and Bolts of Subcutaneous Therapy.
    Duff C; Ballow M
    Immunol Allergy Clin North Am; 2020 Aug; 40(3):527-537. PubMed ID: 32654697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 11. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
    Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
    J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
    Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
    Front Immunol; 2020; 11():981. PubMed ID: 32670265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.
    Kan AKC; Leung GMK; Chiang V; Au EYL; Lau CS; Li PH
    Front Immunol; 2022; 13():984110. PubMed ID: 36591300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
    Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
    Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes.
    Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O
    Allergy Asthma Clin Immunol; 2022 Dec; 18(1):110. PubMed ID: 36566213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain.
    Alsina L; Montoro JB; Moral PM; Neth O; Pica MO; Sánchez-Ramón S; Presa M; Oyagüez I; Casado MÁ; González-Granado LI
    Eur J Health Econ; 2022 Apr; 23(3):551-558. PubMed ID: 34546485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Blood Transfus; 2020 Mar; 18(2):96-105. PubMed ID: 32271703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.